Iort denied as not medically necessary by Aetna?
Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna considers IORT medically necessary for select early-stage breast cancer patients meeting TARGIT-A inclusion criteria: age ≥50, unifocal invasive ductal carcinoma, T1 (≤2cm), node-negative, hormone-receptor positive, HER2-negative, no extensive intraductal component. IORT may be delivered as single-fraction at lumpectomy (boost) or as primary partial-breast irradiation. Aetna considers IORT investigational/experimental for most non-breast indications (rectal, glioblastoma, sarcoma, recurrent rectal/pelvic) absent specific guideline support.
What works in the appeal
TARGIT-A 5-yr long-term (Vaidya BMJ 2020;370:m2836) — non-inferior local control vs WBRT for selected patients meeting TARGIT-A criteria, sustained at 12-yr follow-up (Vaidya 2024). ELIOT 5-yr + 10-yr (Veronesi Lancet Oncol 2013;14:1269; Orecchia 2021) — Italian electron IORT outcomes for selected low-risk profile. GEC-ESTRO consensus on partial-breast irradiation 2010/2024 update (Strnad). ASTRO APBI Consensus Statement 2017/update — IORT category eligibility table. NCCN Breast Cancer v2.2024 lists IORT as APBI option meeting selection criteria. For rectal IORT cite NCCN Rectal Cancer v3.2024 (locally advanced + R0 close margin) and Calvo et al EJC 2014 IORT outcomes. Document staging completion (sentinel node, IHC), final pathology with margins, multidisciplinary tumor board recommendation. Submit ABS / ASTRO / ASCO position statements where applicable.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →